OBJECTIVE: To introduce a novel preclinical animal model of psoriatic arthritis (PsA) in R26Stat3Cstopfl/fl CD4Cre mice, and to investigate the role of Th17 cytokines in the disease pathogenesis. METHODS: We characterized a novel murine model of Th17-driven cutaneous and synovio-entheseal disease directed by T cell-specific expression of a hyperactive Stat3 allele. By crossing R26Stat3Cstopfl/fl CD4Cre mice onto an interleukin-22 (IL-22)-knockout background or treating the mice with a neutralizing antibody against IL-17, we interrogated how these Th17 cytokines could contribute to the pathogenesis of PsA. RESULTS: R26Stat3Cstopfl/fl CD4Cre mice developed acanthosis, hyperkeratosis, and parakeratosis of the skin, as well as enthesitis/tendinitis and periarticular bone erosion in different joints, accompanied by osteopenia. T cell-specific expression of a hyperactive Stat3C allele was found to drive the augmented Th17 response in these animals. Careful characterization of the mouse bone marrow revealed an increase in osteoclast progenitor (OCP) and RANKL-producing cells, which contributed to the osteopenia phenotype observed in the mutant animals. Abrogation of the Th17 cytokines IL-17 or IL-22 improved both the skin and bone phenotype in R26Stat3Cstopfl/fl CD4Cre mice, revealing a central role of Th17 cells in the regulation of OCP and RANKL expression on stromal cells. CONCLUSION: Perturbation of the IL-23/Th17 axis instigates Th17-mediated inflammation in R26Stat3Cstopfl/fl CD4Cre mice, leading to cutaneous and synovio-entheseal inflammation and bone pathologic features highly reminiscent of human PsA. Both IL-17A and IL-22 produced by Th17 cells appear to play critical roles in promoting the cutaneous and musculoskeletal inflammation that characterizes PsA.
OBJECTIVE: To introduce a novel preclinical animal model of psoriatic arthritis (PsA) in R26Stat3Cstopfl/fl CD4Cre mice, and to investigate the role of Th17 cytokines in the disease pathogenesis. METHODS: We characterized a novel murine model of Th17-driven cutaneous and synovio-entheseal disease directed by T cell-specific expression of a hyperactive Stat3 allele. By crossing R26Stat3Cstopfl/fl CD4Cre mice onto an interleukin-22 (IL-22)-knockout background or treating the mice with a neutralizing antibody against IL-17, we interrogated how these Th17 cytokines could contribute to the pathogenesis of PsA. RESULTS: R26Stat3Cstopfl/fl CD4Cre mice developed acanthosis, hyperkeratosis, and parakeratosis of the skin, as well as enthesitis/tendinitis and periarticular bone erosion in different joints, accompanied by osteopenia. T cell-specific expression of a hyperactive Stat3C allele was found to drive the augmented Th17 response in these animals. Careful characterization of the mouse bone marrow revealed an increase in osteoclast progenitor (OCP) and RANKL-producing cells, which contributed to the osteopenia phenotype observed in the mutant animals. Abrogation of the Th17 cytokines IL-17 or IL-22 improved both the skin and bone phenotype in R26Stat3Cstopfl/fl CD4Cre mice, revealing a central role of Th17 cells in the regulation of OCP and RANKL expression on stromal cells. CONCLUSION: Perturbation of the IL-23/Th17 axis instigates Th17-mediated inflammation in R26Stat3Cstopfl/fl CD4Cre mice, leading to cutaneous and synovio-entheseal inflammation and bone pathologic features highly reminiscent of human PsA. Both IL-17A and IL-22 produced by Th17 cells appear to play critical roles in promoting the cutaneous and musculoskeletal inflammation that characterizes PsA.
Authors: Shigetoshi Sano; Keith Syson Chan; Steve Carbajal; John Clifford; Mary Peavey; Kaoru Kiguchi; Satoshi Itami; Brian J Nickoloff; John DiGiovanni Journal: Nat Med Date: 2004-12-12 Impact factor: 53.440
Authors: B Frediani; A Allegri; P Falsetti; L Storri; S Bisogno; F Baldi; P Filipponi; R Marcolongo Journal: J Rheumatol Date: 2001-01 Impact factor: 4.666
Authors: Philip J Mease; Iain B McInnes; Bruce Kirkham; Arthur Kavanaugh; Proton Rahman; Désirée van der Heijde; Robert Landewé; Peter Nash; Luminita Pricop; Jiacheng Yuan; Hanno B Richards; Shephard Mpofu Journal: N Engl J Med Date: 2015-10 Impact factor: 91.245
Authors: Kristian Reich; April W Armstrong; Peter Foley; Michael Song; Yasmine Wasfi; Bruce Randazzo; Shu Li; Y-K Shen; Kenneth B Gordon Journal: J Am Acad Dermatol Date: 2017-01-02 Impact factor: 11.527
Authors: Richard J Cuthbert; Evangelos M Fragkakis; Robert Dunsmuir; Zhi Li; Mark Coles; Helena Marzo-Ortega; Peter V Giannoudis; Elena Jones; Yasser M El-Sherbiny; Dennis McGonagle Journal: Arthritis Rheumatol Date: 2017-08-08 Impact factor: 10.995
Authors: Christopher T Ritchlin; Sally A Haas-Smith; Ping Li; David G Hicks; Edward M Schwarz Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808
Authors: Allison C Billi; Jessica E Ludwig; Yi Fritz; Richard Rozic; William R Swindell; Lam C Tsoi; Dennis Gruzska; Shahla Abdollahi-Roodsaz; Xianying Xing; Doina Diaconu; Ranjitha Uppala; Maya I Camhi; Philip A Klenotic; Mrinal K Sarkar; M Elaine Husni; Jose U Scher; Christine McDonald; J Michelle Kahlenberg; Ronald J Midura; Johann E Gudjonsson; Nicole L Ward Journal: J Clin Invest Date: 2020-06-01 Impact factor: 14.808
Authors: Katharine Lu Yang; Alannah Lejeune; Gregory Chang; Jose U Scher; Sergei B Koralov Journal: Semin Immunopathol Date: 2021-02-10 Impact factor: 11.759
Authors: Sarah M Wade; Mary Canavan; Trudy McGarry; Candice Low; Siobhan C Wade; Ronan H Mullan; Douglas J Veale; Ursula Fearon Journal: Ann Rheum Dis Date: 2019-01-09 Impact factor: 19.103
Authors: Dennis G McGonagle; Iain B McInnes; Bruce W Kirkham; Jonathan Sherlock; Robert Moots Journal: Ann Rheum Dis Date: 2019-07-05 Impact factor: 19.103